An Understanding of Biologics & Biosimilars
|
|
- Emily Miles
- 7 years ago
- Views:
Transcription
1 An Understanding of Biologics & Biosimilars Emily Alexander Director, Regional Lead, U.S. Regulatory Affairs, AbbVie Hayden Rhudy Director, Therapeutic Area Strategies, AbbVie
2 QUESTIONS? To ask a question or make a comment, please type it in the Questions box on the right of your screen
3 Agenda Overview of Biologics Introduction to Biosimilars Open Policy Questions Related to Biosimilars Q&A 3
4 Biologics Are Far More Complex Than Conventional Medicines Conventional drugs (small-molecule, chemically synthesized medicines) Biologics (large molecule medicines) Monoclonal Antibody Aspirin 180 Daltons and Zero Amino Acids 148,000 Daltons and 1,330 Amino Acids Small, simple molecules Often tablets or creams Made through simple chemical reactions Large, complex molecules Often injected or infused Grown in living organisms 4
5 Examples of Biologics Vaccines Human growth hormones Interferons Thrombolytics (Clot Busters ) Insulins Botulinum toxins Monoclonal antibodies And many more! Biologics treat a wide array of conditions, including cancer, multiple sclerosis, rheumatoid arthritis, ulcerative colitis, diabetes, spasticity, psoriasis, cystic fibrosis, respiratory virus Hundreds of biologics are in development to treat areas of unmet medical needs, including Alzheimer s disease 5
6 How are biologics different from small molecules? 6
7 Generic Copy of Small-Molecule Medicine: SAMENESS Small molecule medicines have simple structures and are made through relatively simple manufacturing processes (that aren t sensitive to changes) Identical copy can be made by unrelated manufacturers (i.e., a generic copy); approved on basis of sameness Generic will have identical clinical effect in any indication (or disease) Automatic substitution at pharmacy results 7
8 Biosimilar Copy of Biologic: SIMILARITY Biologics have large, complex structures and are made through complex manufacturing processes (that are very sensitive to small changes) Only a similar version can be created; impossible for an identical copy to be made May have small differences in clinical effect; approval of all indications is not automatic Automatic substitution is not typically allowed for biologics; requires a higher standard of evidence in the United States 8
9 U.S. Biosimilar Regulation Generics have been on the market in the U.S. for many decades; most policy decisions are relatively settled Policymakers recognized the need for a separate pathway for biosimilars from generics because of the different policy questions posed by a product that is similar but not the same FDA did not have authority to approve biosimilars until March 2010, when Congress enacted the Biologics Price Competition and Innovation Act To date, no biosimilars have been approved (but several applications are pending) This new type of product and new approval standard (similarity) raises many new policy questions that will impact patients, regulators, physicians, pharmacists, and many others! 9
10 Important Policy Issues for Individuals living with Spinal Cord Injuries/Disorders Interchangeability: This year, the FDA will be deciding what standards must be met for a biosimilar medicine to be determined interchangeable with the original biologic medicine. Rigorous Testing for Each Condition: The FDA will be determining whether drug companies must conduct rigorous clinical testing to prove that a biosimilar works in each and every condition Naming: The FDA will decide whether biosimilars will have the same name as their reference product. Substitution/Notification: State legislation has been proposed to regulate the substitution of biosimilars with the reference product. 10
11 Request to Congress: Call to Action Please hold oversight hearings on this important process and urge the FDA to release clear guidance as soon as possible that ensure patient safety, patient access to the right biologic medicines, patient choice and full transparency. Choice should be at the center of any decision to substitute or switch therapies and should only be decided by the consumer and provider. Consumer choice needs to be preserved and regulatory decisions must be based on sound science. Biosimilar regulations must put consumer safety first. Policymakers and regulators must address appropriate consumer safety and efficacy concerns as they relate to decisions around interchangeability, clinical indications, labeling, naming and substitution. Particular attention must be given to assure that rigorous clinical testing proves that a biosimilar works safely in each and every condition or disease for which it is approved to be prescribed, as well as in each distinct group of individuals with that disease. Ensure pharmacists maintain records of substitutions for significant periods of time would allow the medical community to track long-term treatment outcomes of biosimilars.
12 Roll on Capitol Hill, 2015 June 7-10, 2015 Over 100 advocates participate from across the country for over 200 scheduled meetings with Members of Congress and Congressional staffers to advocate on healthcare, transportation, and disability rights issues that impact access, mobility and independence of all those impacted by spinal cord injuries and disorders. Sunday June 7: Arrival and Welcome Reception Monday June 8: Education Sessions, Speaker Panels and Presentations, Advocacy Training Tuesday June 9: Capitol Hill Meetings followed by Congressional Awards Reception Wednesday June 10: Advocate Recognition Breakfast /
13 THANK YOU QUESTIONS? To ask a question or make a comment, please type it in the Questions box on the right of your screen abennewith@unitedspinal.org
Biologics Biosimilars
Biologics Biosimilars Q u e st i o n s Po l i c y S a fe t y What are biosimilars? Biosimilars are sometimes incorrectly and inappropriately called generic versions of original biological medicines. But
More informationArthritis Foundation Position Statement on Biosimilar Substitution
Arthritis Foundation Position Statement on Biosimilar Substitution The Affordable Care Act creates a regulatory pathway for the approval of a new generation of biologic medications called biosimilars.
More informationUnderstanding specialty drugs
Group Benefits Understanding specialty drugs What your pharmaceutical benefits plan may look like over the next decade Between 2011 and 2014, the percentage of total drug spend represented by specialty
More informationOFFICE OF INSPECTOR GENERAL
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL THE ORPHAN DRUG ACT IMPLEMENTATION AND IMPACT MAY 2001 OEI-09-00-00380 OFFICE OF INSPECTOR GENERAL The mission of the Office of Inspector
More informationBiological. Medicines. A Focus on Biosimilar. Medicines
TM Biological Medicines TM EuropaBio is the voice of the European biotech Industry. It represents the interests of the industry towards the European institutions so that legislation encourages and enables
More informationFREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM
FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM ABBVIE EMPLOYEES WANT TO KNOW What s New in 2015? AbbVie is making changes in its pharmacy benefit program to ensure our medical
More informationPrescription Drug Plan
Prescription Drug Plan The prescription drug plan helps you pay for prescribed medications using either a retail pharmacy or the mail order program. For More Information Administrative details and procedures
More informationStem Cell Quick Guide: Stem Cell Basics
Stem Cell Quick Guide: Stem Cell Basics What is a Stem Cell? Stem cells are the starting point from which the rest of the body grows. The adult human body is made up of hundreds of millions of different
More informationSTATE POLICY ADVOCACY PRIORITIES. American Academy of Dermatology Association
STATE POLICY ADVOCACY PRIORITIES American Academy of Dermatology Association Access to Pharmaceuticals/Cost Transparency AADA collaborates with manufacturers, the health care community, policymakers, private
More informationPrescription Plan FAQ s
Prescription Plan FAQ s What is a specialty medication? Specialty medication is the term used to describe certain medications and a set of services designed to meet the particular needs of people who take
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationPRESCRIPTION DRUG RIDER. Beechcraft
PRESCRIPTION DRUG RIDER Beechcraft If You have Medicare or will become Eligible for Medicare in the next twelve (12) months, Federal law gives You choices about Your prescription drug coverage. Please
More informationWinter 2013. Changing landscapes, pipeline products and plan sponsor impact
Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster
More informationUniversity of Nebraska Prescription Drug Program 2014
University of Nebraska Prescription Drug Program 2014 The University of Nebraska s prescription benefit program is administered by CVS Caremark, a leading national provider of prescription drug benefit
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More information800 17th Street, NW Suite 1100, Washington, DC 20006
800 17th Street, NW Suite 1100, Washington, DC 20006 September 3, 2015 Mr. Andrew Slavitt Acting Administrator, Centers for Medicare & Medicaid Services Department of Health and Human Services Hubert H.
More informationMULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs
More informationNeurodegenerative diseases Includes multiple sclerosis, Parkinson s disease, post-polio syndrome, rheumatoid arthritis, lupus
TIRR Memorial Hermann is a nationally recognized rehabilitation hospital that returns lives interrupted by neurological illness, trauma or other debilitating conditions back to independence. Some of the
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More informationHow To Understand And Understand Biosimilars
Welcome to Biosimilars 20/20, presented by the Specialty Pharma Education Center (SPEC) in partnership with the Specialty Pharma Journal (SPJ). Please note that this is a preliminary agenda that is subject
More informationAdapting Pharmaceutical Reimbursement Policies to Manage Spending on High-Cost Drugs
Adapting Pharmaceutical Reimbursement Policies to Manage Spending on High-Cost Drugs Elizabeth Docteur, Principal, Elizabeth Docteur Consulting Ruth Lopert, Deputy Director, Pharmaceutical Policy & Strategy
More informationRMIP Prescription Plan FAQ's
RMIP Prescription Plan FAQ's A new U.S. Pharmacy Benefit Manager has been selected for January 1, 2015 - CVS/caremark. 1) Why is the RMIP changing to CVS/caremark? The Express Scripts contract ends on
More informationMedical Matters Action Checklists
Medical Matters Action Checklists The following Action Checklists are included in Chapter 5: Medical History Personal Medication Record Health Care Power of Attorney Medical Orders (Do Not Resuscitate/POLST)
More informationNew York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
More informationOverview of the Specialty Drug Trend
WHITE PAPER Overview of the Specialty Drug Trend Succeeding In The Rapidly Changing U.S. Specialty Market 1 Specialty drugs are prescribed to treat complex conditions such as cancer, HIV and inflammatory
More informationNew York State Auto Dealers Association Group Insurance Trust (GIT) Prescription Drug Coverage Summary
New York State Auto Dealers Association Group Insurance Trust (GIT) Prescription Drug Coverage Summary Effective January 1, 2014, all pharmacy coverage will be administered by Express Scripts and its affiliates.
More informationSpecialty Drug Care: Case management services in Quebec
Specialty Drug Care: Case management services in Quebec QUEBEC SUPPORTING HEALTHIER OUTCOMES Your health benefit plan is designed to provide you and your family with financial protection for a variety
More informationMedicare Part D: Coverage of Drugs under Part B versus Part D
Medicare Part D: Coverage of Drugs under Part B versus Part D The Part D outpatient drug benefit enacted as part of the 2003 Medicare Prescription Drug, Improvement, and Modernization Act (MMA) (P.L. 108-73)
More informationHow To Get A Chronic Illness Benefit From The Discovery Health Medical Scheme
Cover for medicine and treatment of chronic conditions 2014 Cover for medicine and treatment of chronic conditions 22 November 2013 Page 1 of 16 Cover for medicine and treatment of chronic conditions Overview
More informationBriefing Paper on Biological and Biosimilar Medicines
Briefing Paper on Biological and Biosimilar Medicines Contents With our thanks IAPO would like to thank all those involved in planning this Toolkit and supporting its development. A full list of acknowledgements
More informationCore therapeutic areas
Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014
More informationEMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
More information5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned
PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We
More informationStatement Of. For. U.S. House of Representatives Energy and Commerce Committee Subcommittee on Oversight and Investigations.
Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Energy and Commerce Committee Subcommittee on Oversight and Investigations Hearing on: Counterfeit Drugs: Fighting
More informationBiologics and biosimilars. An overview
Biologics and biosimilars An overview Contents An introduction to biotechnology... 3 A brief history of medicine development... 4 What are biologic medicines?... 5 How are biologic medicines developed?...
More informationCoventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health
More informationFrom the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts
RSPT 2217 & Principles Gardenhire Chapter 1; p. 1-10 From the Text Key Terms and page 2 Orphan Drugs Table 1-1; page 6 Abbreviations Table 1-2; page 8 Aerosolized Agents Table 1-3; page 9 Drug: Pharmacology:
More informationApplication for Blue Shield of California Medicare Supplement plans
Application for Blue Shield of California Medicare Supplement plans FOR OFFICE USE ONLY Here's how to apply Accept. code Plan type Market code 1 Provide ALL requested information and print clearly in blue
More informationREGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm)
REGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm) (See also General Regulations) MCP1 Definition The degree of Master of Clinical Pharmacy (MClinPharm) is a postgraduate degree awarded
More informationYour Specialty Medication Handbook
Your Specialty Medication Handbook What s Inside Welcome... 3 You can count on special care... 4 Specialty medications present special challenges Get support from the specialty care management program
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Special Committee on Aging. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Special Committee on Aging Hearing on: 10 Years Later: A Look at the Medicare Prescription Drug Program 2:30 p.m. 366 Dirksen
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationNeurodegenerative diseases Includes multiple sclerosis, Parkinson s disease, postpolio syndrome, rheumatoid arthritis, lupus
TIRR Memorial Hermann is a nationally recognized rehabilitation hospital that returns lives interrupted by neurological illness, trauma or other debilitating conditions back to independence. Some of the
More informationNeurodegenerative diseases Includes multiple sclerosis, Parkinson s disease, postpolio syndrome, rheumatoid arthritis, lupus
TIRR Memorial Hermann is a nationally recognized rehabilitation hospital that returns lives interrupted by neurological illness, trauma or other debilitating conditions back to independence. Some of the
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationPHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
More informationFREE PRESCRIPTION DISCOUNT CARD AVAILABLE TO WELD COUNTY RESIDENTS
FREE PRESCRIPTION DISCOUNT CARD AVAILABLE TO WELD COUNTY RESIDENTS Money is tight for everyone these days. Many families work hard to stay within a budget, and, if they are lucky, they are also able to
More informationIllinois Department of Revenue Regulations TITLE 86: REVENUE CHAPTER I: DEPARTMENT OF REVENUE
Illinois Department of Revenue Regulations Title 86 Part 530 Section 530.110 Covered Prescription Drugs TITLE 86: REVENUE CHAPTER I: DEPARTMENT OF REVENUE PART 530 SENIOR CITIZENS AND DISABLED PERSONS
More informationOverview of the BCBSRI Prescription Management Program
Definitions Overview of the BCBSRI Prescription Management Program DISPENSING GUIDELINES mean: the prescription order or refill must be limited to the quantities authorized by your doctor not to exceed
More informationAnimal Pharming: The Industrialization of Transgenic Animals December 1999
Animal Pharming: The Industrialization of Transgenic Animals December 1999 Animal pharming, the process of using transgenic animals to produce human drugs, is staking its claim in a lucrative world market.
More information2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
More informationOverview of the BCBSRI Prescription Management Program
Definitions Overview of the BCBSRI Prescription Management Program DISPENSING GUIDELINES mean: the prescription order or refill must be limited to the quantities authorized by your doctor not to exceed
More informationInstitute for Safe Medication Practices
Institute for Safe Medication Practices 1800 Byberry Road, Suite 810 Huntingdon Valley, PA 19006 FOR MORE INFORMATION, CONTACT : Michael A. Donio, MPA Marketing & Consumer Affairs 215-947-7797 Mdonio@ismp.org
More informationFDA Regulation of Follow-On Biologics
Judith A. Johnson Specialist in Biomedical Policy April 26, 2010 Congressional Research Service CRS Report for Congress Prepared for Members and Committees of Congress 7-5700 www.crs.gov RL34045 c11173008
More informationIntroduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs
Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health
More informationSpecialty drug program. Save time. Save money. Feel good.
Specialty drug program Save time. Save money. Feel good. What are specialty drugs? Specialty drugs are used to treat serious or ongoing medical conditions such as multiple sclerosis, hemophilia, hepatitis
More informationEBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013
FINAL EBE 21 August 2013 EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013 Introduction This document seeks
More informationGetting the Medications and Treatments You Need
Neuropathy Action Foundation Awareness Education Empowerment Getting the Medications and Treatments You Need Understanding Your Rights in Arizona As you search for a health insurance plan or coverage for
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More information2014 HOUSE OF DELEGATES Updated: 2/25/2015 Chairman: Glenn Fussell, M.D. Staff: Susan Moore/Patricia Yeatts
Reference Committee A 2014 HOUSE OF DELEGATES Updated: 2/25/2015 Chairman: Glenn Fussell, M.D. Staff: Susan Moore/Patricia Yeatts Title/Action Referral Status Completed Resolution 101A.14 (Transparency
More informationRE: Essential Health Benefits: Follow Up from the October 2014 Patient Coalition Meeting
Mr. Kevin Counihan Marketplace Chief Executive Officer (CEO) Centers for Medicare & Medicaid Services 7501 Wisconsin Avenue Bethesda, MD 20814 November 18, 2014 RE: Essential Health Benefits: Follow Up
More informationRoche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine
More informationAfter a decade of relative stability as increasing use of
RESEARCH BRIEF NO. 5 APRIL 2015 Rx Costs: A Primer for Health Care Advocates After a decade of relative stability as increasing use of generics significantly moderated spending, drug costs are set to increase
More informationMESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools.
MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET Good Health. Good Business. Great Schools. MESSA Saver Rx Prescription Drug Program The MESSA Saver Rx Prescription Drug Program is made available by a Group
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationTreatment of Chronic Pain: Our Approach
Treatment of Chronic Pain: Our Approach Today s webinar was coordinated by the National Association of Community Health Centers, a partner with the SAMHSA-HRSA Center for Integrated Health Solutions SAMHSA
More informationStatement BAR CODE LABEL REQUIREMENTS FOR HUMAN DRUG AND BIOLOGIC PRODUCTS
Statement on BAR CODE LABEL REQUIREMENTS FOR HUMAN DRUG AND BIOLOGIC PRODUCTS Edith Rosato, R.Ph. Vice President Pharmacy Affairs National Association of Chain Drug Stores Alexandria, VA July 26,2002 Submitted
More informationValue added services of pharmaceutical fullline wholesalers. Contact GIRP for discussing partnerships + 32 2 777 99 77 girp@girp.
Value added services of pharmaceutical fullline wholesalers Contact GIRP for discussing partnerships + 32 2 777 99 77 girp@girp.org Selected examples from GIRP s integrated member companies: Please note
More informationTreatment options a simple guide
Guide Treatment options a simple guide To decide which treatment is right for you, a good starting point is to know what options you have and to understand the pros and cons of each one. People respond
More informationTHE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme
THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to
More informationSpecialty Drug Hyperinflation:
Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System Specialty drugs 1 offer important hope for many patients with complex, hard-to-treat illnesses. While the price of specialty
More information2015 -- S 0169 S T A T E O F R H O D E I S L A N D
======== LC000 ======== 01 -- S 01 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO INSURANCE - ACCIDENT AND SICKNESS INSURANCE POLICIES Introduced
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationTestimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC
Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Committee on Oversight and Government Reform Domestic Policy Subcommittee U.S. House of
More informationMonoclonal antibody (mab) products are currently a fast
Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,
More informationGrowth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
More informationA Comparison of US and EU Biosimilars Regimes
A Comparison of US and EU Biosimilars Regimes summary statement Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different
More informationWESTCHESTER COMMUNITY COLLEGE Valhalla, NY 10595. COURSE TITLE: Pharmacology (for Nursing and Health Fields) COURSE NUMBER: Biology 202
WESTCHESTER COMMUNITY COLLEGE Valhalla, NY 10595 SYLLABUS FORM COURSE TITLE: Pharmacology (for Nursing and Health Fields) COURSE NUMBER: Biology 202 1. NAME OF COURSE: Pharmacology (for Nursing and Health
More informationUrinary Incontinence FAQ Sheet
Urinary Incontinence FAQ Sheet Are you reluctant to talk to your doctor about your bladder control problem? Don t be. There is help. Loss of bladder control is called urinary incontinence. It can happen
More informationStatement of the American Pharmacists Association Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA Executive Vice President and CEO.
Statement of the American Pharmacists Association Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA Executive Vice President and CEO FDA Public Hearing on Using Innovative Technologies and Other Conditions
More informationGOVERNMENTAL AFFAIRS AND LEGAL MATTERS (A)
GOVERNMENTAL AFFAIRS AND LEGAL MATTERS (A) 50 Medical Liability Insurance Education for Employed Physicians Introduced by the Fifth and Sixth Districts RESOLVED, That the Medical Society of the State of
More informationThe Value of Membership
The Value of Membership S i n c e 1 9 9 7, the He a l thc a re I n st i t ute o f New J e r sey (HINJ ) ha s s er ved a s t h e vo i ce o f the state s l i fe sci en c es i ndustr y. H I N J s eek s to
More informationRIDER ADDING PRESCRIPTION DRUG COVERAGE
Group Health Incorporated (hereinafter referred to as GHI ) 441 Ninth Avenue New York, NY 10001 RIDER ADDING PRESCRIPTION DRUG COVERAGE RETAIL DRUG PROGRAM Deductible: Generic Drugs: Brand Name Preferred
More informationPain Management Regulations Affect More Than Pain Management Specialists January 2012. Of counsel to
Pain Management Regulations Affect More Than Pain Management Specialists January 2012 LINDA A. KEEN MSN, JD, LHCRM LAW OFFICE OF LINDA A. KEEN P.A. TALLAHASSEE, FL Of counsel to Pain Management Regulations
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationA Regulatory Framework for Nurse Practitioners in British Columbia
2855 Arbutus Street Vancouver, BC V6J 3Y8 Tel 604.736.7331 1.800.565.6505 www.crnbc.ca A Regulatory Framework for Nurse Practitioners in British Columbia In December 2000, the Ministry of Health announced
More informationSPECIALTY TREND MANAGEMENT
SPECIALTY TREND MANAGEMENT Table of Contents Specialty drives pharmacy trend... Chapter 1 Managing price, mix and utilization... Chapter 2 Expand preferred drug strategies... Chapter 3 Cost-effective site
More informationThe Excelsior Solutions Difference
The Excelsior Solutions Difference Expert pharmacy benefit management (PBM) consulting team In-house pharmacists, PBM and Medicare Part D experts Former C-level PBM executives averaging 20+ years industry
More informationThe Role of Patient Advocates and the FDA Deborah J. Miller, Ph.D., M.P.H., R.N. Office of Special Health Issues
The Role of Patient Advocates and the FDA Deborah J. Miller, Ph.D., M.P.H., R.N. Office of Special Health Issues Ovarian Cancer National Alliance 15 th Annual Conference July 16, 2012 Outline Brief history
More informationHouse Resolution No. 37
california legislature regular session House Resolution No. Introduced by Assembly Member Hill August, House Resolution No. Relative to umbilical cord blood banking. WHEREAS, Since the first umbilical
More informationUser Centric Product Design for Greater End-User Adherence. Primary Data on a 360 o Analysis
User Centric Product Design for Greater End-User Adherence Primary Data on a 360 o Analysis Panel Discussion Gary Hall, Jr. 10 time Olympic Medalist & Diabetes Patient Russell Rothman, MD, MPP Assistant
More informationRheumatology. Rheumatoid Arthritis
Rheumatology Rheumatoid Arthritis The Rheumatology service specialises in the diagnosis and treatment of diseases affecting the musculoskeletal system. Other than providing inpatient and outpatient consultation,
More informationFAMILY CONTACT INFORMATION
FAMILY CONTACT INFORMATION -------------------- PLEASE COMPLETE THIS FORM IN BLACK INK ONLY -------------------- Date Account # Children Names DOB Gender School Goes By Cell Phone # Email Address Please
More information2015 Annual Convention
2015 Annual Convention Date: Monday, October 12, 2015 Time: 8:00 am 9:30 am Location: Gaylord National Harbor Resort and Convention Center, National Harbor 3 Title: Activity Type: Speaker: How to Create
More informationNational Commtity Pharmacists Association B. Douglas Hoey, R.Ph., M.B.A. June 28,200O 11:25 a.m. (presentation)
. National Commtity Pharmacists Association Good morning. My name is Douglas Hoey, I m a pharmacist on the staff of the National Community Pharmacists Association. On behalf of NCPA, we would like to thank
More informationAccess to Prescription Drugs in New Brunswick
Access to Prescription Drugs in New Brunswick Discussion Paper Department of Health June 2015 Department of Health Published by: Department of Health Government of New Brunswick P. O. Box 5100 Fredericton,
More informationAnnual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationHINJ and New Jersey s Life Sciences Community
HINJ and New Jersey s Life Sciences Community Since 1997, the HealthCare Institute of New Jersey (HINJ) has ser ved as the leading voice of the state s life sciences industr y. HINJ seeks to expand patient
More information